RHD*01
(ISBT table: RHD partial D v5.0)

This entry is the RHD reference allele.

standard RHD, standard RHD (RHD*01), wild type D,
Download VCF file

Molecular data

Nucleotides:

Amino acids:

Hybrid allele encompassing at least one RHCE exon: no

Comments on the molecular basis:

  • sometimes additional IVS5-38del4 with R1r or R1R1 or R1R2 phenotype
  • intronic polymorphism -28G > C was present in 13/13 DCe haplotypes, 13/43 Dce and 1/8 DcE haplotypes; additional intronic IVS2+36A>G mutation in one sample heterozygous for RHef00008 and RHef00442; additional 3'UTR mutation Exon 10 +1377G>A mutation in one sample heterozygous for RHef00008 and RHef00442; additional intronic IVS5+12G>A in one sample heterozygous with RHef00077
  • RHD-specific miRNA expression level quantification compared to RHef00122
  • description of normal promoter sequence
  • intronic sequence established by long range PCR and NGS for R2 haplotype with Genbank accession numbers MG944309 and for R1, R0 and R2 haplotypes with Genbank accession number MG944308

Extracellular position of one or more amino acid substitutions:

  • NA, reference protein

Splicing:

  • NA, reference protein

Unconventional prediction methods:

  • NA, reference protein

Phenotype

Main D phenotype: D positive (last update: Nov. 17, 2019)
Reports by D phenotype
Other RH phenotypes: RH:-2, -3, -4, -5, 12, -19, -23, -31, -54,
  • RH:-2 inferred from the reported RHCE phenotypes of the carriers
  • RH:-3 inferred from the reported RHCE phenotypes of the carriers
  • RH:-4 inferred from the reported RHCE phenotypes of the carriers
  • RH:-5 inferred from the reported RHCE phenotypes of the carriers
  • RH:12
  • RH:-19
  • RH:-23
  • RH:-31
  • RH:-54
Serology with monoclonal anti-D
  • 0 monoclonal IgG anti-D non-reactive with variant, out of 12 monoclonal IgG anti-D tested, sample used as control (Table S2)
  • sample used as control (Table II)
  • 0 monoclonal IgG anti-D non-reactive with variant, 1 sample tested with 2 panels of monoclonal anti-D (17 IgG, 4 IgM) (Table 3)
Antigen Density (Ag/RBC)
  • 13283 Ag/RBC, RH:1,2,-3,4,5 sample used as control; derived from the results obtained with 59 of the 59 monoclonal IgG anti-D tested
  • 24509 Ag/RBC, RH:1,2,3,4,5 sample used as control; derived from the results obtained with 59 of the 59 monoclonal IgG anti-D tested
  • 22778 Ag/RBC, RH:1,2,-3,-4,5 sample used as control; derived from the results obtained with 59 of the 59 monoclonal IgG anti-D tested
  • 19710 Ag/RBC, RH:1,-2,3,4,5 sample used as control; derived from the results obtained with 59 of the 59 monoclonal IgG anti-D tested
  • 23240 Ag/RBC, RH:1,-2,-3,4,5 sample used as control; derived from the results obtained with 59 of the 59 monoclonal IgG anti-D tested
  • Ag/RBC, epitope density profile with 59 monoclonal IgG anti-D (Figure 1)
  • range: 17401 - 20807, median 19024 Ag/RBC, range with different monoclonal anti-D from one ccDEe sample used as control
  • 20166 Ag/RBC, determined from the results of 55 monoclonal anti-D out of the 55 tested (results above a cutoff); RH:1,-2,-3,4,5 sample used as control
  • 10429 Ag/RBC, 1 R1r sample used as control
  • 13645 Ag/RBC, RH:1,2,-3,4,5 sample used as control
  • range: 6437 - 17634, median: 11668 Ag/RBC, 499 "normal D" R1r samples, 2 monoclonal anti-D
  • range: 13617 - 22988, median: 18221 Ag/RBC, 437 "normal D" R2r samples, 2 monoclonal anti-D
  • range: 10578 - 28041, median: 19191 Ag/RBC, 480 "normal D" R0r samples, 2 monoclonal anti-D
  • 16500 Ag/RBC, DCcEe control, estimated antigen density
  • 16884 Ag/RBC, 1 RH:1,2,-3,4,5 sample used as control
  • mean: 22105, SD: 2210 Ag/RBC, with 4 monoclonal anti-D; 3 RH:1,-2,-3,4,5 control samples (S2)
  • 20726 Ag/RBC, 1 R0r sample used as control, with 12 anti-D (Table S1)
More phenotype data
Rhesus Similarity Index

  • 0.74 (RH:1,-2,-3,4,5 sample used as control)
  • 0.845 (Rhesus Index expected for standard RhD)
  • 0.9 (RH:1,2,-3,4,5 sample used as control)
  • 0.84 (RH:1,2,3,4,5 sample used as control) (RH:1,2,-3,-4,5 sample used as control)
  • 0.87 (RH:1,-2,3,4,5 sample used as control)
  • 0.88 (RH:1,-2,-3,4,5 sample used as control)
  • 0.89 (R1r sample)

Haplotype

Main CcEe phenotype association: Ce and cE are the most common associations in Caucasians, ce is the most common association in Afro-Caribbean, but all combinations are possible, see articles (last update: Nov. 9, 2019)
Number of samples reported by haplotype
ce Ce cE CE
ce 111 12 4 0
Ce 0 0 0
cE 0 0
CE 0
Reports by CcEe phenotype
  • with Ccee
    • 12 samples
  • with ce
    • 0 samples (number of samples could not be counted) (Figure 2; presented as a general association, no sample count)
    111 samples
  • with Ce
    • 0 samples (Figure 2; presented as a general association, no sample count)
  • with cE
    • 0 samples (Figure 2; presented as a general association, no sample count)
  • with CE
    • 0 samples (Figure 2; presented as a general association, no sample count)
  • with ccEe
    • 4 samples
Main allele association: RHCE*02, RHCE*03, RHCE*01, RHCE*01.20
Reports by allele association
  • RHCE*01.20.01 (RHCE*733G)
    • 2 samples
    • 1 sample
    • 53 samples
    • 5 samples
  • RHCE*01
    • 2 samples
    • 2 samples
    • 1 sample
    • 4 samples
    • 5 samples
    • 0 samples
    • 5 samples
  • RHCE*ceCF (RHCE*01.20.06)
    • 1 sample
  • RHCE*03
    • 7 samples
    • 13 samples
    • 1 sample
    • 0 samples
    • 8 samples
  • RHCE*01.20.02 (RHCE*48C,733G)
    • 2 samples
    • 2 samples
    • 1 sample
  • RHCE*02
    • 2 samples
    • 7 samples
    • 1 sample
    • 1 sample
    • 0 samples
    • 14 samples
  • RHCE*04
    • 1 sample
    • 0 samples
    • 3 samples
  • RHCE*01.01 RHCE*ce(48)
    • 2 samples
    • 1 sample
    • 0 samples
    • 2 samples
  • RHCE*Ce(462T)
    • 1 sample
  • RHCE*ce48C, 105T
    • 1 sample
  • RHCE*ce(48C,733G,1006T) (RHCE*ce.20.03)
    • 2 samples
    • 8 samples
  • RHCE*ceMO
    • 8 samples
  • RHCE*cEMI
    • 1 sample
  • RHCE*ceAR
    • 0 samples
  • RHCE*ceTI
    • 2 samples
  • RHCE*cE(916)
    • 4 samples
  • RHCE*ce733 or RHCE*ce48,733,1006
    • 2 samples
  • RHCE*01 or RHCE*ce48,733,1006
    • 1 sample
  • RHCE*02 or RHCE*ce48,733,1006
    • 2 samples
  • RHCE*ceHAR or RHCE*ce48C
    • 1 sample
  • RHCE*02 or RHCE*ce48C
    • 1 sample
  • RHCE*02 or RHCE*03
    • 1 sample
    • 1 sample
  • RHCE*02 or RHCE*01
    • 1 sample
    • 1 sample
  • RHCE*02 or RHCE*ceTI
    • 2 samples
  • RHCE*02 or RHCE*ce733G
    • 1 sample
  • RHCE*ceAG or RHCE*ce733G
    • 1 sample
  • RHCE*ce48C
    • 1 sample
  • RHCE*ceAG
    • 1 sample
  • RHCE*ce48,733,1006
    • 1 sample
  • RHCE*01.01 or RHCE*ce479G, 733G
    • 1 sample
  • RHCE*ceMO or RHCE*03
    • 1 sample
    • 1 sample
  • RHCE*ceMO or RHCE*CeRN
    • 1 sample
  • RHCE*ce(340,733) or RHCE*03
    • 2 samples
  • RHCE*ceMO or RHCE*ce-D(5)-ce
    • 1 sample
  • RHCE*CeRN or RHCE*ce(733,748)
    • 1 sample
  • RHCE*CeRN or RHCE*ce-(4-9)-ce
    • 1 sample
  • RHCE*CeRN or RHCE*ceMO
    • 1 sample
  • RHCE*cE(733G)
    • 1 sample
  • RHCE*ceVS.01(307T)
    • 1 sample
  • RHCE*ceVS.09
    • 1 sample
  • RHCE*Ce(712G)
    • 1 sample
  • RHCE*Ce−D(9)−Ce
    • 1 sample
  • RHCE*CeVA
    • 1 sample
  • RHCE*cE.14
    • 1 sample
  • RHCE*cE.19
    • 1 sample
  • RHCE*CeCX
    • 1 sample
  • RHCE*Ce−D(2)−Ce
    • 1 sample
  • RHCE*CeN.03
    • 1 sample
  • RHCE*CeN.04
    • 1 sample
  • RHCE*CeN.05
    • 1 sample
  • RHCE*CeN.07
    • 1 sample
  • RHCE*CeN.08
    • 1 sample
  • RHCE*CeRN
    • 1 sample
  • RHCE*cE.18
    • 1 sample
  • RHCE*Ce(1137A) or RHCE*CE
    • 1 sample
  • RHCE*cE or RHCE*ceVS.02
    • 1 sample
  • RHCE*ce or RHCE*cEN.02
    • 1 sample
  • RHCE*ceEK or RHCE*ce
    • 1 sample
  • RHCE*ce or RHCE*ce(48C,712G,733G,787G,800A)
    • 1 sample
  • RHCE*CeN.08 or RHCE*ceAR
    • 1 sample
  • RHCE*ceVS.01 or RHCE*ceVS.09
    • 1 sample
  • RHCE*ce or RHCE*ceJAL
    • 1 sample
  • RHCE*01 or RHCE*01.01
    • 1 sample
  • RHCE*ce or RHCE*ce(285T)
    • 1 sample
  • RHCE*Ce or RHCE*ceLOCR
    • 1 sample
  • RHCE*Ce or RHCE*ceSL.02
    • 1 sample
  • RHCE*Ce or Duplication RHCE*ce
    • 1 sample
  • RHCE*Ce.26 or RHCE*ce
    • 1 sample
  • RHCE*cEEW or RHCE*ce
    • 1 sample
  • RHCE*Ce(436T) or RHCE*ce
    • 1 sample
  • RHCE*Ce(462T) or RHCE*ce
    • 1 sample
  • RHCE*Ce(1153C) or RHCE*ce
    • 1 sample
  • RHCE*Ce−D(2)−Ce or RHCE*ce
    • 1 sample
  • RHCE*CeN.08 or RHCE*ce
    • 1 sample
  • RHCE*CeRN or RHCE*ce
    • 1 sample
  • RHCE*cE or RHCE*ce
    • 1 sample
  • RHCE*cE(92C) or RHCE*Ce
    • 1 sample
  • RHCE*cE(281C,282T) or RHCE*Ce
    • 1 sample
  • RHCE*cE(341A) or RHCE*ce
    • 1 sample
  • RHCE*cE(697G) or RHCE*ce
    • 1 sample
  • RHCE*Ce or RHCE*ceVS.04
    • 1 sample
  • RHCE*cE(361T) or RHCE*ceVS.03
    • 1 sample
  • RHCE*ceVS.01 or RHCE*ceVS.03
    • 1 sample
  • RHCE*ceVS.01 or RHCE*ceTI
    • 1 sample
  • RHCE*ceVS.01 or RHCE*ceBI
    • 1 sample
  • RHCE*ce.01 or RHCE*ce.16
    • 2 samples
  • RHCE*cE or RHCE*cE(602C)
    • 1 sample

Alloimmunization

Antibodies in carriers
Antibody specificity: D (RH1)
Summary: not considered at risk for allo-anti-D (last update: Nov. 17, 2019)
Detailed information
    Noizat-Pirenne F et al. Transfus Clin Biol (2011)
  • Ab specificity: D (RH1)
  • Number (auto- or allo-): 8
  • Number listed as allo-:
  • Number listed as auto-:
  • Number of carriers of the allele assessed:
  • DAT: ND
  • Autologuous control: ND
  • Elution: ND
  • Autoadsorption: ND
  • Titer: ND
  • Was anti-LW excluded?: ND
  • Other antibodies detected: ND
  • Cross matches (with Ab and RBCs from different partial types): ND
  • Transfusion history: ND, probable
  • Pregnancy history:
  • Anti-D Ig history: ND
  • Context: among 17 SCD patients with anti-D
  • Hemolytic consequences:
  • Comment:
    Dezan MR et al. Blood Cells Mol Dis (2017)
  • Ab specificity: D (RH1)
  • Number (auto- or allo-):
  • Number listed as allo-: 10 (listed as allo-anti-D or probable allo-anti-D)
  • Number listed as auto-: 1
  • Number of carriers of the allele assessed:
  • DAT: 46.2% of D+ patients with anti-D in this study had positive DAT (which patients are not specified)
  • Autologuous control: ND
  • Elution: anti-D was eluted in one sample and considered auto-anti-D
  • Autoadsorption: ND
  • Titer: ND
  • Was anti-LW excluded?: ND
  • Other antibodies detected: see reference for details
  • Cross matches (with Ab and RBCs from different partial types): ND
  • Transfusion history: yes, number and phenotypes ND
  • Pregnancy history:
  • Anti-D Ig history: ND, probably none
  • Context: SCD patient
  • Hemolytic consequences:
  • Comment: 3 samples listed with allo-anti-D or probable allo-anti-D, despite apparently standard RHD allele; authors underline that "self-directed anti-D may have been missed"
    Sippert E et al. Blood Transfus (2015)
  • Ab specificity: D (RH1)
  • Number (auto- or allo-):
  • Number listed as allo-: 2 (samples heterozygous with RHef00008)
  • Number listed as auto-:
  • Number of carriers of the allele assessed:
  • DAT: ND
  • Autologuous control: ND
  • Elution: ND
  • Autoadsorption: ND
  • Titer: ND
  • Was anti-LW excluded?: ND
  • Other antibodies detected: ND
  • Cross matches (with Ab and RBCs from different partial types): ND
  • Transfusion history: yes, number and phenotypes ND
  • Pregnancy history:
  • Anti-D Ig history: ND, probably none
  • Context: among 48 SCD patients with RH antibodies despite antigen-matched transfusion protocols
  • Hemolytic consequences: none of the 13 patients with delayed hemolytic transfusion reactions or decreased survival of transfused RBCs had this allele
  • Comment: study does not detail serology for each sample, but mentions performing DAT, autologuous control, eluate studies and adsorption on autologuous RBCs to aid the differenciation of autoantibodies and alloantibodies
    Westhoff CM et al. Transfusion (2013)
  • Ab specificity: D (RH1)
  • Number (auto- or allo-):
  • Number listed as allo-: 1 (listed as allo-anti-D, patient heterozygous for RHef00442 and RHef00008)
  • Number listed as auto-:
  • Number of carriers of the allele assessed:
  • DAT:
  • Autologuous control:
  • Elution:
  • Autoadsorption:
  • Titer:
  • Was anti-LW excluded?:
  • Other antibodies detected:
  • Cross matches (with Ab and RBCs from different partial types):
  • Transfusion history:
  • Pregnancy history:
  • Anti-D Ig history:
  • Context: among 27 patients referred with different RH alloantibodies, who were found to have RHCE*ceMO allele
  • Hemolytic consequences:
  • Comment:
    Chou ST et al. Blood (2013)
  • Ab specificity: D (RH1)
  • Number (auto- or allo-): 8
  • Number listed as allo-:
  • Number listed as auto-:
  • Number of carriers of the allele assessed: 31
  • DAT:
  • Autologuous control:
  • Elution:
  • Autoadsorption:
  • Titer:
  • Was anti-LW excluded?:
  • Other antibodies detected:
  • Cross matches (with Ab and RBCs from different partial types):
  • Transfusion history:
  • Pregnancy history:
  • Anti-D Ig history:
  • Context: SCD children
  • Hemolytic consequences: 3 had delayed hemolytic transfusion reactions
  • Comment: anti-D detected in 8 of 31 patients with one conventional and one variant RHD alleles
    Chou ST et al. Blood (2013)
  • Ab specificity: D (RH1)
  • Number (auto- or allo-): 13
  • Number listed as allo-:
  • Number listed as auto-:
  • Number of carriers of the allele assessed: 57
  • DAT:
  • Autologuous control:
  • Elution:
  • Autoadsorption:
  • Titer:
  • Was anti-LW excluded?:
  • Other antibodies detected:
  • Cross matches (with Ab and RBCs from different partial types):
  • Transfusion history:
  • Pregnancy history:
  • Anti-D Ig history:
  • Context: SCD children
  • Hemolytic consequences: at least 6 had delayed hemolytic transfusion reactions
  • Comment: anti-D detected in 13 of 57 patients with conventional RHD only
    O'Suoji C et al. Pediatr Blood Cancer (2013)
  • Ab specificity: D (RH1)
  • Number (auto- or allo-):
  • Number listed as allo-:
  • Number listed as auto-: 1
  • Number of carriers of the allele assessed: ND
  • DAT: ND
  • Autologuous control: ND
  • Elution: ND
  • Autoadsorption: ND
  • Titer: ND
  • Was anti-LW excluded?: ND
  • Other antibodies detected: anti-RH2, anti-KEL6, anti-Bg, auto-anti-RH5
  • Cross matches (with Ab and RBCs from different partial types): ND
  • Transfusion history: 188 RBC units, chronic transfusion program
  • Pregnancy history:
  • Anti-D Ig history: ND, probably none
  • Context: SCD child
  • Hemolytic consequences: unknown
  • Comment:
Antibodies in D negative recipients

Alloimmunization in recipients: expected to be possible, see phenotype data

Reports

Summary: reference allele, described in all populations (last update: May 2, 2020)
Detailed reports
  • 42/58 random donors carrying the allele (regardless of the allele in trans) Malian
  • 23/310 (2 heterozygous with RHef00059, 1 with RHef00313; 20 could be RHef00442 associated with RHef00058 or, less likely, RHef00313 associated with RHef00056) among 1702 samples tested for the combined presence of RHD c.602G and c.667G (700 Dutch White, 310 South African Black, 319 South African Asians, 197 Curacao Black, 176 Ethiopian Black) South African, Black
  • 1/197 (heterozygous with RHef00313) among 1702 samples tested for the combined presence of RHD c.602G and c.667G (700 Dutch White, 310 South African Black, 319 South African Asians, 197 Curacao Black, 176 Ethiopian Black) Curacao (Black)
  • 3/319 (2 heterozygous with RHef00059, 1 with RHef00313) among 1702 samples tested for the combined presence of RHD c.602G and c.667G (700 Dutch White, 310 South African Black, 319 South African Asians, 197 Curacao Black, 176 Ethiopian Black) South African (Asian)
  • 5/167 (2 heterozygous with RHef00313, 2 with RHef00315; 1 could be RHef00442 associated with RHef00058 or, less likely, RHef00313 associated with RHef00056) among 1702 samples tested for the combined presence of RHD c.602G and c.667G (700 Dutch White, 310 South African Black, 319 South African Asians, 197 Curacao Black, 176 Ethiopian Black) Ethiopian (Black)
  • 5 or 6/10 (1 heterozygous with RHef00447, 1 sample could be RHef00008 in trans with RHef00317 or RHef00313 with RHef00056) individuals with D positive phenotype Bantu, subgroup Teke, Boma from villages in the north of Léfini river
  • 9 or 10/10 (5 heterozygous with RHef00008, 1 sample could be RHef00442 in trans to RHef00020 or RHef00093 in trans to RHef00008) individuals with D positive phenotype Bantu, subgroup Teke, Nziku from villages in the south of Gamboma city
  • 5/10 (1 heterozygous with RHef00018) individuals with D positive phenotype Bantu, subgroup Teke, Wumu from villages in the south of Ngabé city
  • 7/10 (5 heterozygous with RHef00008, 1 with RHef00313) individuals with D positive phenotype Bantu, subgroup Teke, Kukuya from villages around Djambala city
  • 15/60 (7/21 donors, heterozygous with RHef00058; 8/39 patients, heterozygous with RHef00058) among 60 individuals (21 donors, 39 patients) phenotyped as RH:54 and/or submitted for investigation to determine the RH genotype in the USA population (inferred African American)
  • 62/62 (including 2 heterozygous with RHef00107 and 1 with RHef00447) D positive random donors included for the development of a genotyping assay in the Dutch population
  • 1 sample among SCD patients with Ab in the USA population, Illinois
  • 235 alleles in 226 patients, SCD children systematically genotyped in an alloimmunization study in the USA population (Philadelphia)
  • 15/27 (13 heterozygous with RHef00008) among 27 patients referred with different RH alloantibodies, who were found to have RHCE*ceMO allele African American
  • 25/50 (19 heterozygous with RHef00008) among 50 donors, the majority referred because of ambiguous RH5 antigen typing, found to have RHCE*ceMO (44 with RHef00008, 6 with RHef00442) in the USA population
  • 44/316 (18 heterozygous with RHef00447, 6 with RHef00058, 6 with RHef00313, 4 with RHef00317, 4 with RHef0020, 3 with RHef00067, 1 with RHef00018, 1 with RHef00046, 1 with RHef00009) among 316 (280 D positive and 36 D negative) donors genotyped African descent (FY:-1,-2) in the French population
  • 96/127 (50 homo- or hemizygous, 46 in trans to a variant allele) The cohort was composed of 77 Tswa from Congo, 36 Biaka from Central African Republic, 14 Mbuti from Democratic Republic of the Congo. Pygmoid Central African
  • 152/220 (64 hemi- or homozygous, 88 in trans to a variant allele) The cohort was composed of 164 Teke-Congolese (ethnic groups: 60 Akwa, 52 Mbochi, 52 Kuyu) from Congo, 19 Mandenka from Senegal, 25 Yoruba from Nigeria, 12 Bantu from Kenya. Nonpygmoid Central African
  • 12/48 (2 heterozyguous with RHef00008) among 48 SCD patients with RH antibodies despite antigen-matched transfusion protocols African Brazilian
  • 20 or more/67 among 405 random donor samples used to evaluate RHD zygosity tests (35 typed D negative, 303 typed D positive, 67 of the latter had discordant results with different methods and were sequenced) in the Tunisian population
  • 29/35 had at least one RHef00442 SCD patients with unexplained RH antibodies, explored by NGS sequencing in the Brazilian population, Sao Paolo
  • 200/200 (168 homozygous, 12 hemizygous, 19 heterozygous, 1 DD / D) D positive donors tested by MPLA Chinese, Southern Han
  • 27 homozygote and 40 heterozygote samples among 278 samples selected for the development of nonspecific quantitative next-generation sequencing. (non-random samples, may have been reported in other studies)
Allele or phenotype frequency
  • 0.538 estimated haplotype frequency Malian
  • 0.607 allele frequency among 140 SCD patients African American (in the USA population)
  • 0.639 allele frequency among 480 African American donors African American (in the USA population)
  • 0.554 - 0.848 allele frequency from molecular typing of 46 random samples Fulani Malian
  • 0.416 - 0.500 allele frequency from molecular typing of 101 random samples Dogon Malian

2D diagram

generated using Protter extraintra Met1 Met1 Ser2 Ser2 Ser3 Ser3 Lys4 Lys4 Tyr5 Tyr5 Pro6 Pro6 Arg7 Arg7 Ser8 Ser8 Val9 Val9 Arg10 Arg10 10Arg11 Arg11 Cys12 Cys12 Leu13 Leu13 Pro14 Pro14 Leu15 Leu15 Trp16 Trp16 Ala17 Ala17 Leu18 Leu18 Thr19 Thr19 Leu20 Leu20 20Glu21 Glu21 Ala22 Ala22 Ala23 Ala23 Leu24 Leu24 Ile25 Ile25 Leu26 Leu26 Leu27 Leu27 Phe28 Phe28 Tyr29 Tyr29 Phe30 Phe30 30Phe31 Phe31 Thr32 Thr32 His33 His33 Tyr34 Tyr34 Asp35 Asp35 Ala36 Ala36 Ser37 Ser37 Leu38 Leu38 Glu39 Glu39 Asp40 Asp40 40Gln41 Gln41 Lys42 Lys42 Gly43 Gly43 Leu44 Leu44 Val45 Val45 Ala46 Ala46 Ser47 Ser47 Tyr48 Tyr48 Gln49 Gln49 Val50 Val50 50Gly51 Gly51 Gln52 Gln52 Asp53 Asp53 Leu54 Leu54 Thr55 Thr55 Val56 Val56 Met57 Met57 Ala58 Ala58 Ala59 Ala59 Ile60 Ile60 60Gly61 Gly61 Leu62 Leu62 Gly63 Gly63 Phe64 Phe64 Leu65 Leu65 Thr66 Thr66 Ser67 Ser67 Ser68 Ser68 Phe69 Phe69 Arg70 Arg70 70Arg71 Arg71 His72 His72 Ser73 Ser73 Trp74 Trp74 Ser75 Ser75 Ser76 Ser76 Val77 Val77 Ala78 Ala78 Phe79 Phe79 Asn80 Asn80 80Leu81 Leu81 Phe82 Phe82 Met83 Met83 Leu84 Leu84 Ala85 Ala85 Leu86 Leu86 Gly87 Gly87 Val88 Val88 Gln89 Gln89 Trp90 Trp90 90Ala91 Ala91 Ile92 Ile92 Leu93 Leu93 Leu94 Leu94 Asp95 Asp95 Gly96 Gly96 Phe97 Phe97 Leu98 Leu98 Ser99 Ser99 Gln100 Gln100 100Phe101 Phe101 Pro102 Pro102 Ser103 Ser103 Gly104 Gly104 Lys105 Lys105 Val106 Val106 Val107 Val107 Ile108 Ile108 Thr109 Thr109 Leu110 Leu110 110Phe111 Phe111 Ser112 Ser112 Ile113 Ile113 Arg114 Arg114 Leu115 Leu115 Ala116 Ala116 Thr117 Thr117 Met118 Met118 Ser119 Ser119 Ala120 Ala120 120Leu121 Leu121 Ser122 Ser122 Val123 Val123 Leu124 Leu124 Ile125 Ile125 Ser126 Ser126 Val127 Val127 Asp128 Asp128 Ala129 Ala129 Val130 Val130 130Leu131 Leu131 Gly132 Gly132 Lys133 Lys133 Val134 Val134 Asn135 Asn135 Leu136 Leu136 Ala137 Ala137 Gln138 Gln138 Leu139 Leu139 Val140 Val140 140Val141 Val141 Met142 Met142 Val143 Val143 Leu144 Leu144 Val145 Val145 Glu146 Glu146 Val147 Val147 Thr148 Thr148 Ala149 Ala149 Leu150 Leu150 150Gly151 Gly151 Asn152 Asn152 Leu153 Leu153 Arg154 Arg154 Met155 Met155 Val156 Val156 Ile157 Ile157 Ser158 Ser158 Asn159 Asn159 Ile160 Ile160 160Phe161 Phe161 Asn162 Asn162 Thr163 Thr163 Asp164 Asp164 Tyr165 Tyr165 His166 His166 Met167 Met167 Asn168 Asn168 Met169 Met169 Met170 Met170 170His171 His171 Ile172 Ile172 Tyr173 Tyr173 Val174 Val174 Phe175 Phe175 Ala176 Ala176 Ala177 Ala177 Tyr178 Tyr178 Phe179 Phe179 Gly180 Gly180 180Leu181 Leu181 Ser182 Ser182 Val183 Val183 Ala184 Ala184 Trp185 Trp185 Cys186 Cys186 Leu187 Leu187 Pro188 Pro188 Lys189 Lys189 Pro190 Pro190 190Leu191 Leu191 Pro192 Pro192 Glu193 Glu193 Gly194 Gly194 Thr195 Thr195 Glu196 Glu196 Asp197 Asp197 Lys198 Lys198 Asp199 Asp199 Gln200 Gln200 200Thr201 Thr201 Ala202 Ala202 Thr203 Thr203 Ile204 Ile204 Pro205 Pro205 Ser206 Ser206 Leu207 Leu207 Ser208 Ser208 Ala209 Ala209 Met210 Met210 210Leu211 Leu211 Gly212 Gly212 Ala213 Ala213 Leu214 Leu214 Phe215 Phe215 Leu216 Leu216 Trp217 Trp217 Met218 Met218 Phe219 Phe219 Trp220 Trp220 220Pro221 Pro221 Ser222 Ser222 Phe223 Phe223 Asn224 Asn224 Ser225 Ser225 Ala226 Ala226 Leu227 Leu227 Leu228 Leu228 Arg229 Arg229 Ser230 Ser230 230Pro231 Pro231 Ile232 Ile232 Glu233 Glu233 Arg234 Arg234 Lys235 Lys235 Asn236 Asn236 Ala237 Ala237 Val238 Val238 Phe239 Phe239 Asn240 Asn240 240Thr241 Thr241 Tyr242 Tyr242 Tyr243 Tyr243 Ala244 Ala244 Val245 Val245 Ala246 Ala246 Val247 Val247 Ser248 Ser248 Val249 Val249 Val250 Val250 250Thr251 Thr251 Ala252 Ala252 Ile253 Ile253 Ser254 Ser254 Gly255 Gly255 Ser256 Ser256 Ser257 Ser257 Leu258 Leu258 Ala259 Ala259 His260 His260 260Pro261 Pro261 Gln262 Gln262 Gly263 Gly263 Lys264 Lys264 Ile265 Ile265 Ser266 Ser266 Lys267 Lys267 Thr268 Thr268 Tyr269 Tyr269 Val270 Val270 270His271 His271 Ser272 Ser272 Ala273 Ala273 Val274 Val274 Leu275 Leu275 Ala276 Ala276 Gly277 Gly277 Gly278 Gly278 Val279 Val279 Ala280 Ala280 280Val281 Val281 Gly282 Gly282 Thr283 Thr283 Ser284 Ser284 Cys285 Cys285 His286 His286 Leu287 Leu287 Ile288 Ile288 Pro289 Pro289 Ser290 Ser290 290Pro291 Pro291 Trp292 Trp292 Leu293 Leu293 Ala294 Ala294 Met295 Met295 Val296 Val296 Leu297 Leu297 Gly298 Gly298 Leu299 Leu299 Val300 Val300 300Ala301 Ala301 Gly302 Gly302 Leu303 Leu303 Ile304 Ile304 Ser305 Ser305 Val306 Val306 Gly307 Gly307 Gly308 Gly308 Ala309 Ala309 Lys310 Lys310 310Tyr311 Tyr311 Leu312 Leu312 Pro313 Pro313 Gly314 Gly314 Cys315 Cys315 Cys316 Cys316 Asn317 Asn317 Arg318 Arg318 Val319 Val319 Leu320 Leu320 320Gly321 Gly321 Ile322 Ile322 Pro323 Pro323 His324 His324 Ser325 Ser325 Ser326 Ser326 Ile327 Ile327 Met328 Met328 Gly329 Gly329 Tyr330 Tyr330 330Asn331 Asn331 Phe332 Phe332 Ser333 Ser333 Leu334 Leu334 Leu335 Leu335 Gly336 Gly336 Leu337 Leu337 Leu338 Leu338 Gly339 Gly339 Glu340 Glu340 340Ile341 Ile341 Ile342 Ile342 Tyr343 Tyr343 Ile344 Ile344 Val345 Val345 Leu346 Leu346 Leu347 Leu347 Val348 Val348 Leu349 Leu349 Asp350 Asp350 350Thr351 Thr351 Val352 Val352 Gly353 Gly353 Ala354 Ala354 Gly355 Gly355 Asn356 Asn356 Gly357 Gly357 Met358 Met358 Ile359 Ile359 Gly360 Gly360 360Phe361 Phe361 Gln362 Gln362 Val363 Val363 Leu364 Leu364 Leu365 Leu365 Ser366 Ser366 Ile367 Ile367 Gly368 Gly368 Glu369 Glu369 Leu370 Leu370 370Ser371 Ser371 Leu372 Leu372 Ala373 Ala373 Ile374 Ile374 Val375 Val375 Ile376 Ile376 Ala377 Ala377 Leu378 Leu378 Met379 Met379 Ser380 Ser380 380Gly381 Gly381 Leu382 Leu382 Leu383 Leu383 Thr384 Thr384 Gly385 Gly385 Leu386 Leu386 Leu387 Leu387 Leu388 Leu388 Asn389 Asn389 Leu390 Leu390 390Lys391 Lys391 Ile392 Ile392 Trp393 Trp393 Lys394 Lys394 Ala395 Ala395 Pro396 Pro396 His397 His397 Glu398 Glu398 Ala399 Ala399 Lys400 Lys400 400Tyr401 Tyr401 Phe402 Phe402 Asp403 Asp403 Asp404 Asp404 Gln405 Gln405 Val406 Val406 Phe407 Phe407 Trp408 Trp408 Lys409 Lys409 Phe410 Phe410 410Pro411 Pro411 His412 His412 Leu413 Leu413 Ala414 Ala414 Val415 Val415 Gly416 Gly416 Phe417 Phe417 417 MSSKYPRSVRRCLPLWALTLEAALILLFYFFTHYDASLEDQKGLVASYQVGQDLTVMAAIGLGFLTSSFRRHSWSSVAFNLFMLALGVQWAILLDGFLSQFPSGKVVITLFSIRLATMSALSVLISVDAVLGKVNLAQLVVMVLVEVTALGNLRMVISNIFNTDYHMNMMHIYVFAAYFGLSVAWCLPKPLPEGTEDKDQTATIPSLSAMLGALFLWMFWPSFNSALLRSPIERKNAVFNTYYAVAVSVVTAISGSSLAHPQGKISKTYVHSAVLAGGVAVGTSCHLIPSPWLAMVLGLVAGLISVGGAKYLPGCCNRVLGIPHSSIMGYNFSLLGLLGEIIYIVLLVLDTVGAGNGMIGFQVLLSIGELSLAIVIALMSGLLTGLLLNLKIWKAPHEAKYFDDQVFWKFPHLAVGF MSSKYPRSVRRCLPLWALTLEAALILLFYFFTHYDASLEDQKGLVASYQVGQDLTVMAAIGLGFLTSSFRRHSWSSVAFNLFMLALGVQWAILLDGFLSQFPSGKVVITLFSIRLATMSALSVLISVDAVLGKVNLAQLVVMVLVEVTALGNLRMVISNIFNTDYHMNMMHIYVFAAYFGLSVAWCLPKPLPEGTEDKDQTATIPSLSAMLGALFLWMFWPSFNSALLRSPIERKNAVFNTYYAVAVSVVTAISGSSLAHPQGKISKTYVHSAVLAGGVAVGTSCHLIPSPWLAMVLGLVAGLISVGGAKYLPGCCNRVLGIPHSSIMGYNFSLLGLLGEIIYIVLLVLDTVGAGNGMIGFQVLLSIGELSLAIVIALMSGLLTGLLLNLKIWKAPHEAKYFDDQVFWKFPHLAVGF MSSKYPRSVRRCLPLWALTLEAALILLFYFFTHYDASLEDQKGLVASYQVGQDLTVMAAIGLGFLTSSFRRHSWSSVAFNLFMLALGVQWAILLDGFLSQFPSGKVVITLFSIRLATMSALSVLISVDAVLGKVNLAQLVVMVLVEVTALGNLRMVISNIFNTDYHMNMMHIYVFAAYFGLSVAWCLPKPLPEGTEDKDQTATIPSLSAMLGALFLWMFWPSFNSALLRSPIERKNAVFNTYYAVAVSVVTAISGSSLAHPQGKISKTYVHSAVLAGGVAVGTSCHLIPSPWLAMVLGLVAGLISVGGAKYLPGCCNRVLGIPHSSIMGYNFSLLGLLGEIIYIVLLVLDTVGAGNGMIGFQVLLSIGELSLAIVIALMSGLLTGLLLNLKIWKAPHEAKYFDDQVFWKFPHLAVGF MSSKYPRSVRRCLPLWALTLEAALILLFYFFTHYDASLEDQKGLVASYQVGQDLTVMAAIGLGFLTSSFRRHSWSSVAFNLFMLALGVQWAILLDGFLSQFPSGKVVITLFSIRLATMSALSVLISVDAVLGKVNLAQLVVMVLVEVTALGNLRMVISNIFNTDYHMNMMHIYVFAAYFGLSVAWCLPKPLPEGTEDKDQTATIPSLSAMLGALFLWMFWPSFNSALLRSPIERKNAVFNTYYAVAVSVVTAISGSSLAHPQGKISKTYVHSAVLAGGVAVGTSCHLIPSPWLAMVLGLVAGLISVGGAKYLPGCCNRVLGIPHSSIMGYNFSLLGLLGEIIYIVLLVLDTVGAGNGMIGFQVLLSIGELSLAIVIALMSGLLTGLLLNLKIWKAPHEAKYFDDQVFWKFPHLAVGF

Structure mapping

Movement    Mouse Input    Touch Input
RotationPrimary Mouse ButtonSingle touch
TranslationMiddle Mouse Button or Ctrl+PrimaryTriple touch
ZoomScroll Wheel or Second Mouse Button or Shift+PrimaryPinch (double touch)
SlabCtrl+SecondNot Available

Links

The Human RhesusBase
Genbank: MG944309 MG944308
Erythrogene

References

  1. International Society of Blood Transfusion et al. International Society of Blood Transfusion (ISBT) allele table Online ressource, 1935. — Online ressource — [RHeference]
  2. Ceppellini R et al. AN INTERACTION BETWEEN ALLELES AT THE RH LOCUS IN MAN WHICH WEAKENS THE REACTIVITY OF THE RH(0) FACTOR (D). Proc Natl Acad Sci U S A, 1955. [Citation] [RHeference]
  3. Colin Y et al. Genetic basis of the RhD-positive and RhD-negative blood group polymorphism as determined by Southern analysis. Blood, 1991. [Citation] [RHeference]
  4. Le van Kim C et al. Molecular cloning and primary structure of the human blood group RhD polypeptide. Proc Natl Acad Sci U S A, 1992. [Citation] [RHeference]
  5. Arce MA et al. Molecular cloning of RhD cDNA derived from a gene present in RhD-positive, but not RhD-negative individuals. Blood, 1993. [Citation] [RHeference]
  6. Huang CH et al. Alteration of RH gene structure and expression in human dCCee and DCW-red blood cells: phenotypic homozygosity versus genotypic heterozygosity. Blood, 1996. [Citation] [RHeference]
  7. Flegel WA et al. Primary anti-D immunization by weak D type 2 RBCs. Transfusion, 2000. [Citation] [RHeference]
  8. Okuda H et al. The analysis of nucleotide substitutions, gaps, and recombination events between RHD and RHCE genes through complete sequencing. Biochem Biophys Res Commun, 2000. [Citation] [RHeference]
  9. Wagner FF et al. Weak D alleles express distinct phenotypes. Blood, 2000. [Citation] [RHeference]
  10. Wagner FF et al. The DAU allele cluster of the RHD gene. Blood, 2002. [Citation] [RHeference]
  11. Noizat-Pirenne F et al. Rare RHCE phenotypes in black individuals of Afro-Caribbean origin: identification and transfusion safety. Blood, 2002. [Citation] [RHeference]
  12. Wagner FF et al. RHD allele distribution in Africans of Mali. BMC Genet, 2003. [Citation] [RHeference]
  13. Körmöczi GF et al. A comprehensive analysis of DEL types: partial DEL individuals are prone to anti-D alloimmunization. Transfusion, 2005. [Citation] [RHeference]
  14. Grootkerk-Tax MG et al. RHD(T201R, F223V) cluster analysis in five different ethnic groups and serologic characterization of a new Ethiopian variant DARE, the DIII type 6, and the RHD(F223V). Transfusion, 2006. [Citation] [RHeference]
  15. Esteban R et al. The D category VI type 4 allele is prevalent in the Spanish population. Transfusion, 2006. [Citation] [RHeference]
  16. Yu X et al. Outliers in RhD membrane integration are explained by variant RH haplotypes. Transfusion, 2006. [Citation] [RHeference]
  17. von Zabern I et al. IVS5-38del4 deletion in the RHD gene does not cause a DEL phenotype: relevance for RHD alleles including DFR-3. Transfusion, 2007. [Citation] [RHeference]
  18. Flegel WA et al. DCS-1, DCS-2, and DFV share amino acid substitutions at the extracellular RhD protein vestibule. Transfusion, 2008. [Citation] [RHeference]
  19. Touinssi M et al. Molecular analysis of inactive and active RHD alleles in native Congolese cohorts. Transfusion, 2009. [Citation] [RHeference]
  20. Westhoff CM et al. DIIIa and DIII Type 5 are encoded by the same allele and are associated with altered RHCE*ce alleles: clinical implications. Transfusion, 2010. [Citation] [RHeference]
  21. Krog GR et al. Is current serologic RhD typing of blood donors sufficient for avoiding immunization of recipients? Transfusion, 2011. [Citation] [RHeference]
  22. Noizat-Pirenne F et al. Relevance of RH variants in transfusion of sickle cell patients. Transfus Clin Biol, 2011. [Citation] [RHeference]
  23. Lomas-Francis C et al. DIII Type 7 is likely the original serologically defined DIIIb. Transfusion, 2012. [Citation] [RHeference]
  24. O'Suoji C et al. Alloimmunization in sickle cell anemia in the era of extended red cell typing. Pediatr Blood Cancer, 2013. [Citation] [RHeference]
  25. Daniels G et al. Variants of RhD--current testing and clinical consequences. Br J Haematol, 2013. [Citation] [RHeference]
  26. Westhoff CM et al. RHCE*ceMO is frequently in cis to RHD*DAU0 and encodes a hr(S) -, hr(B) -, RH:-61 phenotype in black persons: clinical significance. Transfusion, 2013. [Citation] [RHeference]
  27. Granier T et al. A comprehensive survey of both RHD and RHCE allele frequencies in sub-Saharan Africa. Transfusion, 2013. [Citation] [RHeference]
  28. Haer-Wigman L et al. RHD and RHCE variant and zygosity genotyping via multiplex ligation-dependent probe amplification. Transfusion, 2013. [Citation] [RHeference]
  29. Chou ST et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood, 2013. [Citation] [RHeference]
  30. Kappler-Gratias S et al. Systematic RH genotyping and variant identification in French donors of African origin. Blood Transfus, 2014. [Citation] [RHeference]
  31. Flegel WA et al. Phasing-in RHD genotyping. Arch Pathol Lab Med, 2014. [Citation] [RHeference]
  32. Jakobsen MA et al. A case of high-titer anti-D hemolytic disease of the newborn in which late onset and mild course is associated with the D variant, RHD-CE(9)-D. Transfusion, 2014. [Citation] [RHeference]
  33. Reid ME et al. Genomic analyses of RH alleles to improve transfusion therapy in patients with sickle cell disease. Blood Cells Mol Dis, 2014. [Citation] [RHeference]
  34. Ba A et al. RH diversity in Mali: characterization of a new haplotype RHD*DIVa/RHCE*ceTI(D2). Transfusion, 2015. [Citation] [RHeference]
  35. Kacem N et al. Paternal RHD zygosity determination in Tunisians: evaluation of three molecular tests. Blood Transfus, 2015. [Citation] [RHeference]
  36. Sippert E et al. Variant RH alleles and Rh immunisation in patients with sickle cell disease. Blood Transfus, 2015. [Citation] [RHeference]
  37. Srivastava K et al. The DAU cluster: a comparative analysis of 18 RHD alleles, some forming partial D antigens. Transfusion, 2016. [Citation] [RHeference]
  38. Stegmann TC et al. Frequency and characterization of known and novel RHD variant alleles in 37 782 Dutch D-negative pregnant women. Br J Haematol, 2016. [Citation] [RHeference]
  39. Thongbut J et al. RHD-specific microRNA for regulation of the DEL blood group: integration of computational and experimental approaches. Br J Biomed Sci, 2017. [Citation] [RHeference]
  40. Ouchari M et al. Serologic and molecular characterization of weak D type 29. Transfusion, 2017. [Citation] [RHeference]
  41. Ji YL et al. RHD genotype and zygosity analysis in the Chinese Southern Han D+, D- and D variant donors using the multiplex ligation-dependent probe amplification assay. Vox Sang, 2017. [Citation] [RHeference]
  42. Dezan MR et al. RHD and RHCE genotyping by next-generation sequencing is an effective strategy to identify molecular variants within sickle cell disease patients. Blood Cells Mol Dis, 2017. [Citation] [RHeference]
  43. Tounsi WA et al. Complete RHD next-generation sequencing: establishment of reference RHD alleles. Blood Adv, 2018. [Citation] [RHeference]
  44. Floch A et al. Comment from Rheference Online ressource, 2020. — Online ressource — [RHeference]
  45. Stef M et al. RH genotyping by nonspecific quantitative next-generation sequencing. Transfusion, 2020. [Citation] [RHeference]

Last update: Jan. 14, 2021